12:00 AM
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BEMA Buprenorphine: Completed Phase III enrollment

BioDelivery completed enrollment of 300 patients with moderate to severe chronic low back pain in the double-blind, placebo-controlled, U.S. Phase III BUP-301...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >